liver disease

Pfizer Selects Final Two Targets in Hepatic Disease Partnership with Wave Life Sciences
Genentic Engineering and Biology News
Mon, 05/7/18 - 10:22 pm
liver disease
Pfizer
Wave Life Sciences
NASH
Conatus Pharma’s Liver Disease Drug Flunks First Phase 2 Test
Xconomy
Thu, 04/5/18 - 11:57 pm
Conatus Pharmaceuticals
clinical trials
Novartis
emricasan
liver disease
hepatitis C
FDA adds black box warning to Intercept's Ocaliva
Biopharma Dive
Thu, 02/1/18 - 09:32 pm
FDA
black box
Intercept Pharma
Ocaliva
liver disease
5 Ways Gilead Sciences Plans to Return to Growth
Motley Fool
Tue, 01/9/18 - 10:55 pm
Gilead Sciences
HIV
liver disease
cell therapy
inflammation
M&A
FDA Warns Doctors After 19 Deaths on Intercept Liver Drug
Bloomberg
Fri, 09/22/17 - 09:16 am
FDA
Intercept Pharma
Ocaliva
liver disease
Cempra Releases Promising Phase II Clinical Trial Results For Anti-NASH Drug
Xtalks
Wed, 10/5/16 - 05:25 pm
Cempra
clinical trials
NASH
liver disease
Solithromycin
Allergan just acquired two companies in one day
Yahoo/Business Insider
Tue, 09/20/16 - 08:54 pm
Allergan
M&A
liver disease
NASH
Akarna Therapeutics
Tobira Therapeutics
2 Hotly Debated Drugs Due For FDA Decisions Next Week
Investors.com
Sat, 05/21/16 - 12:35 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Intercept Pharma
Ocaliva
liver disease
primary biliary cholangitis
Rare liver disorder drug from Jazz wins U.S. approval
Yahoo/Reuters
Wed, 03/30/16 - 09:19 pm
Jazz Pharmaceuticals
FDA
hepatic veno-occlusive disease
liver disease
Defibrotide
2015's Worst Clinical Failures
Motley Fool
Sat, 12/12/15 - 02:01 pm
clinical trials
liver disease
cancer pain
Eli Lilly
Intercept Pharmaceuticals
GW Pharma
Conatus: Emricasan's 4 Indications Present A Lucrative Opportunity In The Liver Disease Market
Seeking Alpha
Sat, 07/18/15 - 10:48 am
Conatus Pharmaceuticals
emricasan
liver disease
NASH
cirrhosis
New market for liver disease spawns race for better testing
Yahoo/Reuters
Wed, 03/18/15 - 08:20 am
liver disease
NASH
diagnostics
Gilead Sciences to liver disease treatment from Phenex for as much as $470 million
Yahoo/AP
Tue, 01/6/15 - 03:36 pm
Gilead Sciences
Phenex
NASH
liver disease
IPO Stock Watch: FibroGen Up With Liver-Disease Field
Investors.com
Tue, 01/6/15 - 08:41 am
IPOs
FibroGen
liver disease
NASH
Takeda recruits GE to help discover new liver treatments
Fierce Biotech
Tue, 11/11/14 - 01:20 pm
Takeda
GE Healthcare
liver disease
diagnostics
R&D
Biotech stocks to watch ahead of liver disease conference
CNBC
Fri, 11/7/14 - 03:54 pm
liver disease
Gilead Sciences
Intercept Pharma
Genfit
Merck
Achillion
AbbVie
NASH
hepatitis B
hepatitis C
The next hepatitis C? NASH
CNBC
Tue, 07/15/14 - 09:48 am
NASH
hepatitis C
liver disease
nonalcoholic steatohepatitis
Genfit
Gilead Sciences
Intercept Pharma
Intercept Pharma, Government Scientists Spar Over Negative Safety of Liver Drug, Emails Show
TheStreet.com
Tue, 05/20/14 - 09:10 am
Intercept Pharma
liver disease
OCA
obeticholic acid
Shire Acquisition Bolsters Its Rare, And Maybe Not-So-Rare, Disease Portfolio
Seeking Alpha
Mon, 05/19/14 - 09:23 am
Shire
M&A
liver disease
Lumena Pharmaceuticals
LUM001
LUM002
obesity
Lumena swings for a $75M IPO to bear down on liver diseases
Fierce Biotech
Thu, 04/3/14 - 09:30 am
IPOs
Lumena Pharmaceuticals
LUM001
liver disease

Pages